prourokinase

pro·ur·o·ki·nase

(prō'yūr-ō-kī'nās),
The precursor of an activator of plasminogen, urokinase.

prourokinase

/pro·uro·ki·nase/ (pro-UK) (pro″u-ro-ki´nās) the single chain proenzyme cleaved by plasmin to form u-plasminogen activator (urokinase); it is slowly activated in the presence of fibrin clots and is used for therapeutic thrombolysis.
References in periodicals archive ?
Intra-arterial prourokinase for acute ischemic stroke.
The human body's fibrinolytic, clot dissolving, system utilises two natural enzymes, tissue plasminogen activator (tPA) and prourokinase (proUK), rather than only one of them.
Electronic auction: state public institution of the saratov region "state agency for centralization of procurement" announces a joint auction in electronic form on the definition of the supplier of the product "supply of the medicinal preparation" prourokinase "
Siadaty, "Therapeutic or preventive procedures associated with prourokinase," BioMedLib Review, vol.
For example, the Prolyse in Acute Cerebral Thromboembolism Trials (PROACT I and II) were randomized, controlled trials that used recombinant prourokinase to treat middle cerebral artery occlusion experienced for a time period of not greater than 6 hours.
Due to frequent hemorrhagic complications streptokinase, urokinase (UK) and prourokinase (r-proUK) are not preferred (Multicentre Acute Stroke Trial--Italy (Mast-I) Group, 1995; Multicentre Acute Stroke Trial--Europe Study Group, 1996; Yasak, Chambers, Davis, and Donnan, 1998).
A Cochrane review on thrombolysis for acute ischaemic stroke included 26 trials with data on 7 152 patients testing urokinase, streptokinase, tPA, recombinant prourokinase or desmoteplase with 56% of all data that came from trials testing tPA--11 trials, 3 977 patients.
Currently, several thrombolytic agents such as streptokinase, urokinase, prourokinase, reteplase (r-PA), alteplase (t-PA), reptilase, brinase and anisoylated purified streptokinase activator complex (APSAC) are available for clinical use (1).
This left seven patients with clinically significant intracranial hemorrhages, a rate of 5%, which the researchers noted was better than the 6% rate that was previously reported for intravenous TPA and the 10% rate in the major prourokinase study.
This left seven clinically significant intracranial hemorrhages, a 5% rate that the researchers noted was better than the 6% rate previously reported for intravenous TPA and the 10% rate in the major prourokinase study.